Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Objectives Trastuzumab deruxtecan (T-DXd) was recently recommended by the Committee for Medicinal Products for Human Use as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, who had received a prior anti-HER2-based regimen. In our study, we evaluated the cos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European journal of health economics 2024-06, Vol.25 (4), p.689-699
Hauptverfasser:	Paulissen, Jeroen H. J., Seddik, Ahmed H., Dunton, Kyle J., Livings, Christopher J., van Hulst, Marinus, Postma, Maarten J., de Jong, Lisa A., Freriks, Roel D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine - economics Ado-Trastuzumab Emtansine - therapeutic use Adult Antineoplastic Agents, Immunological - economics Antineoplastic Agents, Immunological - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Camptothecin - analogs & derivatives Camptothecin - economics Camptothecin - therapeutic use Cost analysis Cost-Benefit Analysis Economic Policy Female Finland Health care expenditures Health Care Management Health Economics Humans Immunoconjugates Medicine Medicine & Public Health Metastasis Middle Aged Monoclonal antibodies Original Paper Pharmacoeconomics and Health Outcomes Public Finance Public Health Quality of life Quality-Adjusted Life Years Receptor, ErbB-2 - metabolism Sensitivity analysis Survival Survival Analysis Targeted cancer therapy Trastuzumab - economics Trastuzumab - therapeutic use Willingness to pay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!